|Videos|June 20, 2016

How Does MCA Work and What Differentiates It From Other Analyses?

Andrew Chasteen from Accelerate Diagnostics, Inc, explains Morphokinetic Cellular Analysis (MCA) and how it differs from other analyses.

Andrew Chasteen from Accelerate Diagnostics, Inc, explains Morphokinetic Cellular Analysis (MCA) and how it differs from other analyses.

Interview Transcript (slightly modified for readability)

“Let’s start with what MCA really is. Morphokinetic Cellular Analysis is an analytical method that includes digital microscopy to acquire images, as well as machine learning algorithms that analyze individual live cells and the microcolony that they grow into, under a variety of different conditions.

The technology tracks, analyzes, and interprets different morphology and kinetic information in order to get details such as mass, division rate, anomalous growth patterns, and even detect heterogeneity.

The technology is different in the detail that it provides versus some of the other technologies that we see in antibiotic susceptibility testing, such nephelometry, or some of the other mechanism-based methods."


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.